Cytodyn Inc (CYDY) 1.1800 $CYDY
CytoDyn to Present at LD Micro Invitational Conference on June 7
GlobeNewswire - Thu Jun 02, 5:30AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that Nader Z. Pourhassan, Ph.D., President and CEO, will present at the LD Micro Invitational Conference on June 7, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time). The conference is being held at the Luxe Sunset Hotel in Los Angeles.
Clinical Abstract from CytoDyn's PRO 140 Phase 2b HIV Monotherapy Trial Now Available on ASM Microbe 2016 Conference Website
GlobeNewswire - Mon May 16, 3:32PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that an abstract featuring clinical data from the Company's PRO 140 monotherapy Phase 2b extension study in patients with HIV is now available online on the ASM Microbe 2016 website at: http://www.abstractsonline.com/pp8/#!/4060/pr...tion/16215.
CytoDyn Announces Investment Community Conference Call for May 11, 2016
GlobeNewswire - Mon May 09, 1:28PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that management will hold an investment community conference call on Wednesday, May 11, 2016, at 1:00 p.m. PT / 4:00 p.m. ET to provide an update on clinical and regulatory developments.
CytoDyn's Compassionate Use Protocol Receives FDA Clearance to Proceed
GlobeNewswire - Tue May 03, 5:00AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that it has received clearance from the FDA to proceed with its compassionate use protocol, which was submitted to the Agency on April 14. The compassionate use protocol will enable the first patient enrolled in the PRO 140_CD02 Phase 3 pivotal trial with PRO 140 in combination with HAART therapy to remain on PRO 140 upon successful conclusion of the Phase 3 trial period.
CytoDyn Reports Complete Viral Load Suppression in HIV-Infected Patients for Up to 20 Months in PRO 140 Monotherapy Extension Study
GlobeNewswire - Mon Apr 18, 5:00AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that 10 HIV-infected patients in its ongoing PRO 140 monotherapy extension study have achieved complete viral load suppression for at least 18 months, with several patients approaching 20 months. This ongoing monotherapy study is an extension of the completed CDI-01 Phase 2b study that evaluated PRO 140 as a monotherapy in treatment-experienced patients with the R5 subtype of HIV. One patient recently dropped out of the extension study following 17 months of full HIV viral load suppression.
CytoDyn Files a Compassionate Use Protocol With FDA
GlobeNewswire - Thu Apr 14, 8:00AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announced today that it filed with the FDA a protocol for a compassionate use of PRO 140 to allow a patient who is reaching the end of the Phase 3 combination study to continue treatment with PRO 140 for an extended period of time. This compassionate use protocol will enable the patient to remain on PRO 140 upon successful conclusion of their 25-week participation in the trial.
Small Company That Could Change the Way HIV is Treated
ACCESSWIRE - Mon Apr 04, 8:03AM CDT
VANCOUVER, WA / ACCESSWIRE / April 4, 2016 / CytoDyn (OTCQB: CYDY) is a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn's lead product candidate, PRO 140, has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments.
CytoDyn to Present PRO 140 Monotherapy Clinical Results at ASM Microbe 2016 Conference
GlobeNewswire - Mon Mar 28, 5:30AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that clinical findings from the Company's PRO 140 monotherapy phase 2b study will be presented in an oral slide session at the ASM Microbe 2016 Conference from June 16 - 20 in Boston, MA.
CytoDyn Announces Investment Community Conference Call for March 24, 2016
GlobeNewswire - Tue Mar 22, 3:01PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that management will hold an investment community conference call on Thursday, March 24, 2016, at 1:00 p.m. PT / 4:00 p.m. ET to provide an update on clinical and regulatory developments.
Emerging Global Trends, A Developing Story - Analyst Comments on Icon Vapor, Titan Medical, Sharkreach and CytoDyn
ACCESSWIRE - Fri Mar 11, 6:40AM CST
NEW YORK, NY / ACCESSWIRE / March 11, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Icon Vapor Inc. (OTC: ICNV), Titan Medical Inc. (OTC: TITXF), Sharkreach Inc. (OTC: SHRK) and CytoDyn Inc. (OTC: CYDY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
HIV / AIDS Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/zx8ggt/hiv_aids) has announced the addition of the "HIV / AIDS - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV / AIDSand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HIV / AIDSOverview - Therapeutics Development - Pipeline Products for HIV / AIDS - Overview - Pipeline Products for HIV / AIDS - Comparative Analysis - HIV / AIDS - Therapeutics under Development by Companies - HIV / AIDS - Therapeutics under Investigation by Universities/Institutes - HIV / AIDS - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - HIV / AIDS - Products under Development by Companies - HIV / AIDS - Products under Investigation by Universities/Institutes - HIV / AIDS - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Abivax S.A. - Adaptimmune Limited - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Altor BioScience Corporation - AltraVax Inc. - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Amplyx Pharmaceuticals, Inc. - Antigen Express, Inc. - Aphios Corporation - Apotex, Inc. - Argos Therapeutics, Inc. - Arno Therapeutics, Inc. - Avexa Limited - BCI Pharma - Beth Israel Deaconess Medical Center, Inc. - BioClonetics Immunotherapeutics, Inc. - Bionor Pharma ASA - Biosantech SA - BioSource Pharm, Inc. - Biotron Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - C4X Discovery Limited - Calimmune, Inc. - Celldex Therapeutics, Inc. - Chipscreen Biosciences Ltd - Cocrystal Pharma, Inc. - CompleGen, Inc. - Critical Outcome Technologies Inc. - CureVac GmbH - Cytodyn Inc. For more information visit http://www.researchandmarkets.com/research/zx8ggt/hiv_aids
ARGS: 7.22 (+0.19), CLDX: 4.51 (-0.21), BMY: 72.94 (-0.47)
Studying the Charts -- New Research on Cardinal Resources, Cannabis Science, OriginClear and CytoDyn
ACCESSWIRE - Tue Feb 02, 6:35AM CST
NEW YORK, NY / ACCESSWIRE / February 2, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Cardinal Resources Inc. (OTC: CDNL), Cannabis Science Inc. (OTC: CBIS), OriginClear Inc. (OTC: OOIL) and CytoDyn Inc. (OTC: CYDY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
A Look Inside the Chart, Technical Insights - Analyst Notes on Hybrid Coating Technologies, Force Protection Video Equipment, CytoDyn and Golden Queen Mining
ACCESSWIRE - Mon Feb 01, 7:35AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Hybrid Coating Technologies Inc. (OTC: HCTI), Force Protection Video Equipment Corp. (OTC: FPVD), CytoDyn Inc. (OTC: CYDY) and Golden Queen Mining Co. Ltd. (OTC: GQMNF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CytoDyn Inc. (OTCQB: CYDY) Analyst Coverage Initiated
ACCESSWIRE - Mon Feb 01, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / CytoDyn Inc. (OTCQB: CYDY) a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced the Company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a Treatment for HIV-1 Infection in Treatment-Experienced Patients with Virologic Failure. While the standard of care for HIV infection has been the combination of medications from different antiretroviral (ART) classes that interfere with different steps of the viral lifecycle, there is now a significant number of long-term survivors who are facing issues of drug resistance and are in need of new treatment options (Pennings 2013, Cossarini et al. 2013). The Company believes this request for Breakthrough Therapy Designation addresses the unmet need for novel therapies for the growing number of heavily treatment-experienced HIV patients, who face a dwindling pool of effective therapeutic options in the face of uncontrolled viral load and low CD4+ T-cell counts.
CytoDyn Reports Full Virologic Suppression in Eleven HIV Patients on PRO 140 Monotherapy for Up to 17 Months
GlobeNewswire - Thu Jan 28, 5:30AM CST
CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that 11 patients have achieved full virologic suppression in the Phase 2b extension study evaluating long-term suppression of HIV replication by PRO 140 monotherapy. These patients self-administered PRO 140 weekly for 14 to 17 months. Using a very sensitive, single-copy HIV-1 RNA assay, seven of 10 patients had less than one viral copy per milliliter in their blood in the most recent month of treatment. The median of the lowest HIV RNA levels detected in these 10 patients was 0.4 viral copies per milliliter of blood.
CytoDyn Files Request for Breakthrough Therapy Designation With the FDA for Use of PRO 140 in HIV Therapy
GlobeNewswire - Fri Jan 22, 5:30AM CST
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced the Company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a Treatment for HIV-1 Infection in Treatment-Experienced Patients with Virologic Failure.
Where We Are Headed - Complementary Research on Trans-Pacific Aerospace Company, Rubicon Minerals, Cellceutix and CytoDyn
ACCESSWIRE - Thu Jan 21, 8:22AM CST
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Trans-Pacific Aerospace Company Inc. (OTC: TPAC), Rubicon Minerals Corp. (OTC: RBYCF), Cellceutix Corp. (OTC: CTIX) and CytoDyn Inc. (OTC: CYDY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
RBY: 0.03 (-0.07)
CytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science Officer
GlobeNewswire - Wed Jan 20, 5:30AM CST
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that it had named Denis R. Burger, Ph.D., who is currently a member of the Company's Board of Directors, as Chief Science Officer (CSO) of CytoDyn. In this capacity, through an expansion of Dr. Burger's existing consulting relationship with the Company, Dr. Burger will assist with the development of PRO 140 for HIV and non-HIV clinical indications, including transplantation, autoimmune diseases and cancer. He recently initiated the Company's evaluation of PRO 140 for Graft vs. Host Disease (GvHD) and the Company's Phase 2 protocol for this transplantation indication for patients requiring bone marrow stem cell transplants. On December 11, 2015, the FDA cleared CytoDyn to proceed into a clinical trial for GvHD. PRO 140 is currently in a pivotal Phase 3 trial for adjunct therapy for HIV patients with FDA approval for this indication expected in 2017.
APTO: 2.98 (+0.02), TRIB: 11.30 (-0.04), OSUR: 7.83 (unch)
CytoDyn Announces HIV-Patients Approaching 17 Months of Complete Viral Suppression With PRO 140 Monotherapy
GlobeNewswire - Tue Jan 19, 5:30AM CST
CytoDyn to file an additional Phase 3 Protocol for HIV Monotherapy
FDA Clears CytoDyn for Relaxed Entry Criteria for Its Ongoing Phase 3 Trial in HIV-Infected Patients
GlobeNewswire - Mon Dec 21, 3:02PM CST
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that the FDA has allowed a significant change to the entry criteria for patients in the Company's ongoing PRO 140 Phase 3 trial. This change allows the Company to enroll patients with resistance to a single antiretroviral drug, significantly expanding the number of patients available for the study.
CytoDyn to Present at LD Micro Invitational Conference on June 7
GlobeNewswire - Thu Jun 02, 5:30AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that Nader Z. Pourhassan, Ph.D., President and CEO, will present at the LD Micro Invitational Conference on June 7, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time). The conference is being held at the Luxe Sunset Hotel in Los Angeles.
Clinical Abstract from CytoDyn's PRO 140 Phase 2b HIV Monotherapy Trial Now Available on ASM Microbe 2016 Conference Website
GlobeNewswire - Mon May 16, 3:32PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that an abstract featuring clinical data from the Company's PRO 140 monotherapy Phase 2b extension study in patients with HIV is now available online on the ASM Microbe 2016 website at: http://www.abstractsonline.com/pp8/#!/4060/pr...tion/16215.
CytoDyn Announces Investment Community Conference Call for May 11, 2016
GlobeNewswire - Mon May 09, 1:28PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that management will hold an investment community conference call on Wednesday, May 11, 2016, at 1:00 p.m. PT / 4:00 p.m. ET to provide an update on clinical and regulatory developments.
CytoDyn's Compassionate Use Protocol Receives FDA Clearance to Proceed
GlobeNewswire - Tue May 03, 5:00AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that it has received clearance from the FDA to proceed with its compassionate use protocol, which was submitted to the Agency on April 14. The compassionate use protocol will enable the first patient enrolled in the PRO 140_CD02 Phase 3 pivotal trial with PRO 140 in combination with HAART therapy to remain on PRO 140 upon successful conclusion of the Phase 3 trial period.
CytoDyn Reports Complete Viral Load Suppression in HIV-Infected Patients for Up to 20 Months in PRO 140 Monotherapy Extension Study
GlobeNewswire - Mon Apr 18, 5:00AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that 10 HIV-infected patients in its ongoing PRO 140 monotherapy extension study have achieved complete viral load suppression for at least 18 months, with several patients approaching 20 months. This ongoing monotherapy study is an extension of the completed CDI-01 Phase 2b study that evaluated PRO 140 as a monotherapy in treatment-experienced patients with the R5 subtype of HIV. One patient recently dropped out of the extension study following 17 months of full HIV viral load suppression.
CytoDyn Files a Compassionate Use Protocol With FDA
GlobeNewswire - Thu Apr 14, 8:00AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announced today that it filed with the FDA a protocol for a compassionate use of PRO 140 to allow a patient who is reaching the end of the Phase 3 combination study to continue treatment with PRO 140 for an extended period of time. This compassionate use protocol will enable the patient to remain on PRO 140 upon successful conclusion of their 25-week participation in the trial.
Small Company That Could Change the Way HIV is Treated
ACCESSWIRE - Mon Apr 04, 8:03AM CDT
VANCOUVER, WA / ACCESSWIRE / April 4, 2016 / CytoDyn (OTCQB: CYDY) is a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn's lead product candidate, PRO 140, has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments.
CytoDyn to Present PRO 140 Monotherapy Clinical Results at ASM Microbe 2016 Conference
GlobeNewswire - Mon Mar 28, 5:30AM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that clinical findings from the Company's PRO 140 monotherapy phase 2b study will be presented in an oral slide session at the ASM Microbe 2016 Conference from June 16 - 20 in Boston, MA.
CytoDyn Announces Investment Community Conference Call for March 24, 2016
GlobeNewswire - Tue Mar 22, 3:01PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that management will hold an investment community conference call on Thursday, March 24, 2016, at 1:00 p.m. PT / 4:00 p.m. ET to provide an update on clinical and regulatory developments.
Emerging Global Trends, A Developing Story - Analyst Comments on Icon Vapor, Titan Medical, Sharkreach and CytoDyn
ACCESSWIRE - Fri Mar 11, 6:40AM CST
NEW YORK, NY / ACCESSWIRE / March 11, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Icon Vapor Inc. (OTC: ICNV), Titan Medical Inc. (OTC: TITXF), Sharkreach Inc. (OTC: SHRK) and CytoDyn Inc. (OTC: CYDY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
HIV / AIDS Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/zx8ggt/hiv_aids) has announced the addition of the "HIV / AIDS - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV / AIDSand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HIV / AIDSOverview - Therapeutics Development - Pipeline Products for HIV / AIDS - Overview - Pipeline Products for HIV / AIDS - Comparative Analysis - HIV / AIDS - Therapeutics under Development by Companies - HIV / AIDS - Therapeutics under Investigation by Universities/Institutes - HIV / AIDS - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - HIV / AIDS - Products under Development by Companies - HIV / AIDS - Products under Investigation by Universities/Institutes - HIV / AIDS - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Abivax S.A. - Adaptimmune Limited - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Altor BioScience Corporation - AltraVax Inc. - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Amplyx Pharmaceuticals, Inc. - Antigen Express, Inc. - Aphios Corporation - Apotex, Inc. - Argos Therapeutics, Inc. - Arno Therapeutics, Inc. - Avexa Limited - BCI Pharma - Beth Israel Deaconess Medical Center, Inc. - BioClonetics Immunotherapeutics, Inc. - Bionor Pharma ASA - Biosantech SA - BioSource Pharm, Inc. - Biotron Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - C4X Discovery Limited - Calimmune, Inc. - Celldex Therapeutics, Inc. - Chipscreen Biosciences Ltd - Cocrystal Pharma, Inc. - CompleGen, Inc. - Critical Outcome Technologies Inc. - CureVac GmbH - Cytodyn Inc. For more information visit http://www.researchandmarkets.com/research/zx8ggt/hiv_aids
ARGS: 7.22 (+0.19), CLDX: 4.51 (-0.21), BMY: 72.94 (-0.47)
Studying the Charts -- New Research on Cardinal Resources, Cannabis Science, OriginClear and CytoDyn
ACCESSWIRE - Tue Feb 02, 6:35AM CST
NEW YORK, NY / ACCESSWIRE / February 2, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Cardinal Resources Inc. (OTC: CDNL), Cannabis Science Inc. (OTC: CBIS), OriginClear Inc. (OTC: OOIL) and CytoDyn Inc. (OTC: CYDY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
A Look Inside the Chart, Technical Insights - Analyst Notes on Hybrid Coating Technologies, Force Protection Video Equipment, CytoDyn and Golden Queen Mining
ACCESSWIRE - Mon Feb 01, 7:35AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Hybrid Coating Technologies Inc. (OTC: HCTI), Force Protection Video Equipment Corp. (OTC: FPVD), CytoDyn Inc. (OTC: CYDY) and Golden Queen Mining Co. Ltd. (OTC: GQMNF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CytoDyn Inc. (OTCQB: CYDY) Analyst Coverage Initiated
ACCESSWIRE - Mon Feb 01, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / CytoDyn Inc. (OTCQB: CYDY) a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced the Company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a Treatment for HIV-1 Infection in Treatment-Experienced Patients with Virologic Failure. While the standard of care for HIV infection has been the combination of medications from different antiretroviral (ART) classes that interfere with different steps of the viral lifecycle, there is now a significant number of long-term survivors who are facing issues of drug resistance and are in need of new treatment options (Pennings 2013, Cossarini et al. 2013). The Company believes this request for Breakthrough Therapy Designation addresses the unmet need for novel therapies for the growing number of heavily treatment-experienced HIV patients, who face a dwindling pool of effective therapeutic options in the face of uncontrolled viral load and low CD4+ T-cell counts.
CytoDyn Reports Full Virologic Suppression in Eleven HIV Patients on PRO 140 Monotherapy for Up to 17 Months
GlobeNewswire - Thu Jan 28, 5:30AM CST
CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that 11 patients have achieved full virologic suppression in the Phase 2b extension study evaluating long-term suppression of HIV replication by PRO 140 monotherapy. These patients self-administered PRO 140 weekly for 14 to 17 months. Using a very sensitive, single-copy HIV-1 RNA assay, seven of 10 patients had less than one viral copy per milliliter in their blood in the most recent month of treatment. The median of the lowest HIV RNA levels detected in these 10 patients was 0.4 viral copies per milliliter of blood.
CytoDyn Files Request for Breakthrough Therapy Designation With the FDA for Use of PRO 140 in HIV Therapy
GlobeNewswire - Fri Jan 22, 5:30AM CST
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced the Company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a Treatment for HIV-1 Infection in Treatment-Experienced Patients with Virologic Failure.
Where We Are Headed - Complementary Research on Trans-Pacific Aerospace Company, Rubicon Minerals, Cellceutix and CytoDyn
ACCESSWIRE - Thu Jan 21, 8:22AM CST
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Trans-Pacific Aerospace Company Inc. (OTC: TPAC), Rubicon Minerals Corp. (OTC: RBYCF), Cellceutix Corp. (OTC: CTIX) and CytoDyn Inc. (OTC: CYDY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
RBY: 0.03 (-0.07)
CytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science Officer
GlobeNewswire - Wed Jan 20, 5:30AM CST
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that it had named Denis R. Burger, Ph.D., who is currently a member of the Company's Board of Directors, as Chief Science Officer (CSO) of CytoDyn. In this capacity, through an expansion of Dr. Burger's existing consulting relationship with the Company, Dr. Burger will assist with the development of PRO 140 for HIV and non-HIV clinical indications, including transplantation, autoimmune diseases and cancer. He recently initiated the Company's evaluation of PRO 140 for Graft vs. Host Disease (GvHD) and the Company's Phase 2 protocol for this transplantation indication for patients requiring bone marrow stem cell transplants. On December 11, 2015, the FDA cleared CytoDyn to proceed into a clinical trial for GvHD. PRO 140 is currently in a pivotal Phase 3 trial for adjunct therapy for HIV patients with FDA approval for this indication expected in 2017.
APTO: 2.98 (+0.02), TRIB: 11.30 (-0.04), OSUR: 7.83 (unch)
CytoDyn Announces HIV-Patients Approaching 17 Months of Complete Viral Suppression With PRO 140 Monotherapy
GlobeNewswire - Tue Jan 19, 5:30AM CST
CytoDyn to file an additional Phase 3 Protocol for HIV Monotherapy
FDA Clears CytoDyn for Relaxed Entry Criteria for Its Ongoing Phase 3 Trial in HIV-Infected Patients
GlobeNewswire - Mon Dec 21, 3:02PM CST
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that the FDA has allowed a significant change to the entry criteria for patients in the Company's ongoing PRO 140 Phase 3 trial. This change allows the Company to enroll patients with resistance to a single antiretroviral drug, significantly expanding the number of patients available for the study.
